<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-038849</identifier>
<setSpec>1137-6821</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Proton pump inhibitors</dc:title>
<dc:description xml:lang="en">In an acid environment platelet aggregation and clotting formation are reduced. Ideally, highest benefits in peptic disease- related digestive hemorrhages (PDRDH) could be reached if intragastric pH was continuously maintained above 6. The H2 antagonists lose their antisecretory potential after a three day treatment. The proton pump inhibitors have a higher and maintained antisecretory potential in comparison to H2 antagonists in PDRDH; their efficiency in the prevention of recurrent disease, reduction of surgery and mortality has been also demonstrated. Several studies have reported the superiority of omeprazole and pantoprazole compared to placebo, specially after endoscopic treatment. Intravenous esomeprazole has shown benefit preventing acid secretion and increasing intragastric pH. A bolus of 80 mg is the dose preferred, followed by constant infusion of esomeprazole 8 mg/hour throughout three days (AU)</dc:description>
<dc:creator>Lanas, A</dc:creator>
<dc:creator>Arroyo, M. T</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El medio ácido disminuye la agregación plaquetaria y la formación del coágulo. El beneficio de los fármacos antisecretores en la hemorragia digestiva por enfermedad péptica (HDA-EP) se alcanzará, de forma ideal, al mantener un pH intragástrico superior 6 de forma constante. Los antagonistas H2 pierden su potencia antisecretora a partir del tercer día de tratamiento. Los inhibidores de la bomba de protones tienen una mayor capacidad antisecretora y más mantenida y han demostrado su eficacia en la prevención de la recidiva, necesidad de cirugía y mortalidad en la HDA-EP. Existen estudios demostrando la superioridad de omeprazol y pantoprazol frente a placebo, especialmente después de tratamiento endoscópico. Esomeprazol por vía intravenosa ha demostrado tener una mayor capacidad para inhibir la secreción ácida y elevar el pH intragástrico. Se recomienda un bolo de 80 mg, seguido de una infusión constante de 8 mg/hora durante tres días (AU)</dc:description>
<dc:source>Emergencias (Sant Vicenç dels Horts);17(4): s55-s58, ago. 2005. ilus</dc:source>
<dc:identifier>ibc-038849</dc:identifier>
<dc:title xml:lang="es">Estudio comparativo de los inhibidores de la bomba de protones en la hemorragia digestiva alta</dc:title>
<dc:subject>^d30587^s22006</dc:subject>
<dc:subject>^d10633^s22012</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d7582^s22031</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d7582^s22063</dc:subject>
<dc:subject>^d10633^s22027</dc:subject>
<dc:subject>^d6623^s22053</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6623^s22027</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:type>article</dc:type>
<dc:date>200508</dc:date>
</metadata>
</record>
</ibecs-document>
